AR087470A1 - Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen - Google Patents

Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen

Info

Publication number
AR087470A1
AR087470A1 ARP120102871A ARP120102871A AR087470A1 AR 087470 A1 AR087470 A1 AR 087470A1 AR P120102871 A ARP120102871 A AR P120102871A AR P120102871 A ARP120102871 A AR P120102871A AR 087470 A1 AR087470 A1 AR 087470A1
Authority
AR
Argentina
Prior art keywords
independently
bifenilenic
pharmaceutical compositions
compositions containing
salts
Prior art date
Application number
ARP120102871A
Other languages
English (en)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR087470A1 publication Critical patent/AR087470A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Sales de los compuestos, una composición farmacéutica que comprende los compuestos o sales, y útiles para el tratamiento de la infección por el virus de hepatitis C (HCV) mediante la administración de los compuestos o sales.Reivindicación 1: Un compuesto de la fórmula (1) en donde cada R es independientemente -CH(R1)-NH-C(O)-OR2; en donde cada R1 es independientemente -CH(OH)-CH3 o -CH(OCH3)-CH3; y cada R2 es independientemente alquilo de 1 a 3 átomos de carbono. Reivindicación 14: Un compuesto de la fórmula (2) o de la fórmula (3): en donde X1 y X2 son independientemente O, SO2, NCH3, CF2, CH2, CH2CH2, o un enlace (es decir, están ausentes); y cada R es independientemente -CH(R1)-NH-C(O)-OR2; en donde cada R1 es independientemente -CH(OH)-CH3 o -CH(OCH3)-CH3; y cada R2 es independientemente alquilo de 1 a 3 átomos de carbono.
ARP120102871A 2011-08-08 2012-08-06 Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen AR087470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515990P 2011-08-08 2011-08-08

Publications (1)

Publication Number Publication Date
AR087470A1 true AR087470A1 (es) 2014-03-26

Family

ID=47668848

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102871A AR087470A1 (es) 2011-08-08 2012-08-06 Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen

Country Status (6)

Country Link
US (1) US8889726B2 (es)
EP (1) EP2741746A4 (es)
AR (1) AR087470A1 (es)
TW (1) TW201321373A (es)
UY (1) UY34245A (es)
WO (1) WO2013022810A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI482766B (zh) 2011-07-09 2015-05-01 Sunshine Lake Pharma Co Ltd As a spiro compound for hepatitis C virus inhibitors
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
WO2014082379A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR101919194B1 (ko) * 2015-09-15 2018-11-15 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US9150554B2 (en) * 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
JP2012526834A (ja) * 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
JP2013518062A (ja) * 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎阻害化合物

Also Published As

Publication number Publication date
US20140171476A1 (en) 2014-06-19
WO2013022810A1 (en) 2013-02-14
US8889726B2 (en) 2014-11-18
EP2741746A4 (en) 2014-12-31
EP2741746A1 (en) 2014-06-18
TW201321373A (zh) 2013-06-01
UY34245A (es) 2013-02-28

Similar Documents

Publication Publication Date Title
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
CR20140301A (es) Derivados de betulina
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR063165A1 (es) Derivados de acido boronico como inhibidores de amidihidrolasa de acidos grasos. composiciones farmaceuticas.
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
ECSP11011398A (es) Inhibidores de beta-secretasa
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
AR085327A1 (es) Inhibidores del virus de la hepatitis c
NZ739248A (en) Inhibitors of hepatitis c virus
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR073117A1 (es) Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios.
AR086773A1 (es) Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure